Medication firm Glenmark Pharmaceuticals on Saturday said it has propelled antiviral medication Favipiravir, under the brand name FabiFlu, for the treatment of patients with gentle to moderate Covid-19 at a cost of about Rs 103 for every tablet.
The medication will be accessible as a 200 mg tablet at a maximum retail price (MRP) of Rs 3,500 for a portion of 34 tablets, Glenmark Pharmaceuticals said.
FabiFlu is the first oral favipiravir-endorsed drug in Quite a while for the treatment of Covid-19, it included.
It is a solution based prescription, with a suggested portion being 1,800 mg twice day by day on the very first moment, trailed by 800 mg twice day by day up to day 14, the medication firm said.
“Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the 1st month itself. We will be closely monitoring the evolving situation and basis of the situation, we will work to scale and meet the healthcare needs of the country”.
The organization is creating the active pharmaceutical ingredients (API) for the item at its Ankleshwar plant, while the definition is being produced at its Baddi plant.
The medication will be accessible both through emergency clinics and the retail channel, Glenmark said.
“Our effort right now is to prioritize manufacturing to ensure FabiFlu is accessible to all patients who need it. Glenmark will certainly make a consideration to support private and public healthcare facilities and arrange for other suitable options as per the need and in time”.
When the question was raised that whether the company is going to collaborate with hospitals in form of a tie up
This approval comes at a time when cases in India are spiraling like never before, putting tremendous pressure on our healthcare system,
Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said
“We chose to initiate work on Favipiravir, as it has proven in-vitro activity against SARS CoV2 virus, which is the virus responsible for Covid-19.
“Second is it has a wide therapeutic safety margin for Covid-19 at the dose that we administer,” Glenmark Pharmaceuticals President India Formulations, Middle East and Africa Sujesh Vasudevan said at an online press conference.
